BeyondSpring (BYSI) Stock Price, News & Analysis

Company Overview

BeyondSpring Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity. Plinabulin is being evaluated in multiple clinical trials for the prevention of chemotherapy-induced neutropenia and as a potential combination therapy in metastatic non-small cell lung cancer. BeyondSpring has secured Fast Track designation from the U.S. Food and Drug Administration for plinabulin’s use in neutropenia prevention, underscoring the agent’s differentiated mechanism of action and its potential to reduce chemotherapy-related complications.

BeyondSpring’s broader pipeline includes bezuclastinib, a selective tyrosine kinase inhibitor being studied for the treatment of advanced systemic mastocytosis and related disorders. This program highlights the company’s strategy of in-licensing or acquiring assets with first-in-class or best-in-class potential. BeyondSpring maintains research collaborations and conducts pharmacology and safety evaluations through its integrated facilities in Suzhou, as well as through partnerships with academic institutions and contract research organizations in North America and Europe.

Founded in 2010, BeyondSpring completed its initial public offering on the NASDAQ in 2019 under the ticker symbol BYSI. The company is led by President and Chief Executive Officer Mitchell Gold, alongside co-founder and Executive Chairman Dr. John Li, supported by a management team with extensive expertise in oncology drug development, regulatory affairs and global commercialization. BeyondSpring continues to advance its pipeline through late-stage clinical programs and regulatory filings, with the goal of bringing novel cancer therapeutics to patients worldwide.

Key Stats

• Today's Range: $1.17 to $1.26
• 50-Day Range: $1.24 to $1.87
• 52-Week Range: $1.16 to $2.44
• Volume: 30,876 shs
• Average Volume: 24,469 shs
• Market Capitalization: $49.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

BeyondSpring Stock Analysis - MarketRank™

BeyondSpring scored higher than 1% of companies evaluated by MarketBeat, and ranked 835th out of 838 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BeyondSpring has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BeyondSpring has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BeyondSpring is -8.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeyondSpring is -8.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.63% of the float of BeyondSpring has been sold short.

Short Interest Ratio / Days to Cover

BeyondSpring has a short interest ratio ("days to cover") of 93.95, which indicates bearish sentiment.

Change versus previous month

Short interest in BeyondSpring has recently increased by 0.62%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeyondSpring does not currently pay a dividend.

Dividend Growth

BeyondSpring does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BeyondSpring insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.31% of the stock of BeyondSpring is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.29% of the stock of BeyondSpring is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 7/22/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BYSI
• CIK: 1677940
• Web: www.beyondspringpharma.com
• Phone: (646) 305-6387
• Fax: 1-646-882-4228
• Employees: 80
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): ($0.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -14.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.09
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: $1.75 million
• Price / Sales: 28.20
• Cash Flow: $0.11 per share
• Price / Cash Flow: 10.91
• Book Value: ($0.59) per share
• Price / Book: -2.03

Miscellaneous

• Outstanding Shares: 41,120,000
• Free Float: 29,068,000
• Market Cap: $49.34 million
• Optionable: Optionable
• Beta: 0.43